You are here: Industry Insights > Phase III

News List

Phase III programme for the use otilimab for rheumatoid arthritis launched europeanpharmaceuticalreview
July 08, 2019
A Phase III clinical development programme testing otilimab in patients with RA has begun.
Mirikizimab moved to Phase III after positive trial findings europeanpharmaceuticalreview
May 24, 2019
Eli Lilly presents new data for their mirikizimab treatment for Crohn’s disease.
AbbVie ends Phase III brain tumour study due to failed primary goal pharmatimes
May 21, 2019
AbbVie has ended its ongoing phase III INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in some patients with newly diagnosed glioblastoma (GBM), the most aggressive cancer that begins within the brain.
Aesica adds development capability with new purpose built facility europeanpharmaceuticalreview
May 07, 2019
Product life cycle services expanded, including for high potent and controlled drugs…
Braeburn and Camurus’ Phase III opioid use disorder trial a success europeanpharmaceuticalreview
May 07, 2019
Braeburn Pharmaceuticals and Camurus announced positive results from Phase 3 trial supporting the safety and efficacy of CAM2038 in opioid use disorder…
Solasia initiates Phase III programme for PledOx biospectrumasia
January 07, 2019
In November 2017, Solasia acquired exclusive development and commercialization rights for PledOx in Japan, Mainland China, Hong Kong, S.A.R., China Region in China, Macau, S.A.R., China Region in China, Taiwan, China Region in China, South Korea and from
Amgen’s Nplate Approved for ITP contractpharma
December 18, 2018
Amgen received approval from the FDA for the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have h
Cambrex Expands Analytical Capabilities at High Point contractpharma
December 13, 2018
Cambrex Corp., a manufacturer of small molecule active pharmaceutical ingredients (APIs), and finished dosage forms, is investing $1 million at its High Point, NC site to add 1,300 sq.-ft.
TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History firstwordpharma
July 10, 2018
Translational Research In Oncology (TRIO) today announced a collaboration with Novartis on its upcoming phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The tr
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study americanpharmaceuticalreview
June 27, 2018
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine

Previous page 1 2 Next page